$IBIO
iBio, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023009707 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.610M $3.525M
YoY Change -70.5% -58.66%
% of Gross Profit
Research & Development $2.360M $2.644M
YoY Change -62.75% -52.37%
% of Gross Profit
Depreciation & Amortization $250.0K $193.0K
YoY Change -69.62% -72.78%
% of Gross Profit
Operating Expenses $4.970M $6.169M
YoY Change -67.26% -56.18%
Operating Profit -$6.169M
YoY Change -49.36%
Interest Expense $30.00K $35.00K
YoY Change -118.99% -86.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$110.0K
YoY Change -47.12%
Pretax Income -$4.930M -$6.279M
YoY Change -71.09% -49.32%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.030M -$7.294M
YoY Change -64.64% -41.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$7.01 -$0.55
COMMON SHARES
Basic Shares Outstanding 16.80M 12.37M
Diluted Shares Outstanding 13.18M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.300M $6.562M
YoY Change -87.17% -86.49%
Cash & Equivalents $4.301M $6.562M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $21.80M $19.29M
YoY Change 1307.36% 721.16%
Inventory $0.00
Prepaid Expenses
Receivables $0.00 $70.00K
Other Receivables $200.0K $1.172M
Total Short-Term Assets $26.26M $27.09M
YoY Change -41.74% -55.08%
LONG-TERM ASSETS
Property, Plant & Equipment $4.219M $4.358M
YoY Change -88.49% -87.4%
Goodwill
YoY Change
Intangibles $5.388M $5.393M
YoY Change 11.07% 9.64%
Long-Term Investments
YoY Change
Other Assets $300.0K $3.303M
YoY Change -95.08% -52.44%
Total Long-Term Assets $14.95M $17.29M
YoY Change -72.49% -68.59%
TOTAL ASSETS
Total Short-Term Assets $26.26M $27.09M
Total Long-Term Assets $14.95M $17.29M
Total Assets $41.21M $44.39M
YoY Change -58.55% -61.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.849M $2.013M
YoY Change -56.64% -61.87%
Accrued Expenses $4.034M $3.821M
YoY Change 7.17% 30.01%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $12.90M $13.70M
YoY Change
Long-Term Debt Due $400.0K $421.0K
YoY Change -98.2% 835.56%
Total Short-Term Liabilities $21.58M $22.28M
YoY Change -29.09% 169.0%
LONG-TERM LIABILITIES
Long-Term Debt $600.0K $1.496M
YoY Change 1900.0% -93.25%
Other Long-Term Liabilities $3.700M $3.225M
YoY Change -32.17% -41.87%
Total Long-Term Liabilities $4.300M $4.721M
YoY Change -21.6% -82.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.58M $22.28M
Total Long-Term Liabilities $4.300M $4.721M
Total Liabilities $25.83M $27.00M
YoY Change -28.1% -24.99%
SHAREHOLDERS EQUITY
Retained Earnings -$288.9M -$282.9M
YoY Change 29.03% 36.75%
Common Stock $304.3M $300.3M
YoY Change 5.8% 4.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.38M $17.39M
YoY Change
Total Liabilities & Shareholders Equity $41.21M $44.39M
YoY Change -58.55% -61.53%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$6.030M -$7.294M
YoY Change -64.64% -41.13%
Depreciation, Depletion And Amortization $250.0K $193.0K
YoY Change -69.62% -72.78%
Cash From Operating Activities -$4.970M -$3.872M
YoY Change -56.79% -34.86%
INVESTING ACTIVITIES
Capital Expenditures $510.0K -$201.0K
YoY Change -114.87% -90.32%
Acquisitions
YoY Change
Other Investing Activities $500.0K $8.040M
YoY Change -87.2% 209.95%
Cash From Investing Activities -$10.00K $8.241M
YoY Change -102.1% 1494.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.740M 1.464M
YoY Change -27500.0% -14740.0%
NET CHANGE
Cash From Operating Activities -4.970M -3.872M
Cash From Investing Activities -10.00K 8.241M
Cash From Financing Activities 2.740M 1.464M
Net Change In Cash -2.240M 5.833M
YoY Change -79.7% -207.28%
FREE CASH FLOW
Cash From Operating Activities -$4.970M -$3.872M
Capital Expenditures $510.0K -$201.0K
Free Cash Flow -$5.480M -$3.671M
YoY Change -32.12% -5.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.47
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.77
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.30
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.20
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.08
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.65
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-3.27
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.62
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.82
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13184000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8719000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10592000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8719000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13184000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8719000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10592000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8719000
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.47
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.77
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.30
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.20
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.08
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.65
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-3.27
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.62
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.57
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.82
dei Entity Central Index Key
EntityCentralIndexKey
0001420720
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
422000
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
false
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2786000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8727158
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12368287
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35023
dei Entity Registrant Name
EntityRegistrantName
iBio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2797813
dei Entity Address Address Line1
EntityAddressAddressLine1
8800 HSC Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Bryan
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77807
dei City Area Code
CityAreaCode
979
dei Local Phone Number
LocalPhoneNumber
446-0027
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
IBIO
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16798014
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6562000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22676000
CY2022Q2 us-gaap Debt Securities Current
DebtSecuritiesCurrent
10845000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
70000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2023Q1 ibio Subscription Receivable Current
SubscriptionReceivableCurrent
260000
CY2022Q2 us-gaap Settlement Assets Current
SettlementAssetsCurrent
5100000
CY2023Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
912000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
921000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1549000
CY2023Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
18368000
CY2022Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
3900000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
27093000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
45070000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3253000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5996000
CY2023Q1 ibio Convertible Promissory Note Receivable And Accrued Interest
ConvertiblePromissoryNoteReceivableAndAccruedInterest
775000
CY2022Q2 ibio Convertible Promissory Note Receivable And Accrued Interest
ConvertiblePromissoryNoteReceivableAndAccruedInterest
1631000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
678000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2786000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3068000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4358000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1373000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5393000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4851000
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
50000
CY2022Q2 us-gaap Security Deposit
SecurityDeposit
29000
CY2022Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
74000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
37314000
CY2023Q1 us-gaap Assets
Assets
44386000
CY2022Q2 us-gaap Assets
Assets
99406000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2013000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4264000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3821000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3764000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
265000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
377000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
91000
CY2023Q1 ibio Equipment Financing Payable Current
EquipmentFinancingPayableCurrent
156000
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
13700000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
22161000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2023Q1 ibio Current Liabilities Related To Assets Held For Sale
CurrentLiabilitiesRelatedToAssetsHeldForSale
1944000
CY2022Q2 ibio Current Liabilities Related To Assets Held For Sale
CurrentLiabilitiesRelatedToAssetsHeldForSale
56000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22276000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30436000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
422000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3225000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3514000
CY2023Q1 ibio Equipment Financing Payable Noncurrent
EquipmentFinancingPayableNoncurrent
283000
CY2023Q1 ibio Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
791000
CY2022Q2 ibio Noncurrent Liabilities Related To Assets Held For Sale
NoncurrentLiabilitiesRelatedToAssetsHeldForSale
1971000
CY2023Q1 us-gaap Liabilities
Liabilities
26997000
CY2022Q2 us-gaap Liabilities
Liabilities
35921000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15818149
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8727158
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
300280000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287619000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-213000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-282907000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223930000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17389000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
63485000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44386000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99406000
CY2023Q1 us-gaap Revenues
Revenues
0
CY2022Q1 us-gaap Revenues
Revenues
1800000
us-gaap Revenues
Revenues
1884000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2644000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3272000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7971000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6265000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3525000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5316000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16407000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14863000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6169000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8588000
us-gaap Operating Expenses
OperatingExpenses
24378000
us-gaap Operating Expenses
OperatingExpenses
21128000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6169000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6788000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24378000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19244000
CY2023Q1 us-gaap Interest Expense
InterestExpense
35000
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
66000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
us-gaap Investment Income Interest
InvestmentIncomeInterest
163000
us-gaap Investment Income Interest
InvestmentIncomeInterest
111000
CY2023Q1 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
-98000
CY2022Q1 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
-98000
CY2023Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0
CY2022Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
2000
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
7000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-110000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
118000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6279000
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6746000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-24379000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-19126000
CY2023Q1 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0
CY2022Q1 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
-1000
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6279000
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6746000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-24379000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-19125000
CY2023Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2022Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
88000
CY2023Q1 ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-6279000
CY2022Q1 ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-6746000
ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-24379000
ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-19213000
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1015000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5644000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-34598000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-14124000
CY2023Q1 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-7294000
CY2022Q1 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-12390000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-58977000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-33337000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7294000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12390000
us-gaap Profit Loss
ProfitLoss
-58977000
us-gaap Profit Loss
ProfitLoss
-33250000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
134000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-103000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
180000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-131000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7127000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12493000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-58764000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33381000
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.47
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.77
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.30
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.20
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.08
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.65
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-3.27
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.82
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13184000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8719000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10592000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8719000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63485000
CY2022Q3 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
1151000
CY2022Q3 ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
650000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1222000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-10000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18130000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
48368000
CY2022Q4 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
3500000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
636000
CY2022Q4 ibio Fractional Share Issued After Reverse Stock Split Value
FractionalShareIssuedAfterReverseStockSplitValue
-39000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1127000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
56000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-33553000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18823000
CY2023Q1 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
4097000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1596000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
113000
CY2023Q1 ibio Reclassficiation Adjustment Gain Loss On Available For Sale Debt Securities
ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities
21000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7294000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17389000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
108568000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
821000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-8940000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
100525000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
967000
CY2021Q4 ibio Adjustments To Additional Paid In Capital Acquisition Of Remaining Portion Of Affiliate
AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
50000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1103000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-27000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-11920000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
90598000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1274000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-103000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12390000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
79380000
us-gaap Profit Loss
ProfitLoss
-58977000
us-gaap Profit Loss
ProfitLoss
-33250000
us-gaap Share Based Compensation
ShareBasedCompensation
3945000
us-gaap Share Based Compensation
ShareBasedCompensation
3198000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
156000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
587000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
290000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
386000
us-gaap Depreciation
Depreciation
508000
us-gaap Depreciation
Depreciation
1532000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
732000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
ibio Accrued Interest Receivable On Convertible Promissory Note Receivable
AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
56000
ibio Accrued Interest Receivable On Convertible Promissory Note Receivable
AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
56000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
67000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
269000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
-98000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
ibio Deferred Financing Costs Amortization Expense
DeferredFinancingCostsAmortizationExpense
160000
ibio Deferred Financing Costs Amortization Expense
DeferredFinancingCostsAmortizationExpense
67000
ibio Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
4915000
ibio Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
0
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
17600000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
565000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
5000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
0
ibio Forgiveness Of Note Payable And Accrued Interest Sba Loan
ForgivenessOfNotePayableAndAccruedInterestSbaLoan
607000
ibio Settlement Of Revenue Contract
SettlementOfRevenueContract
84000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-931000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
890000
ibio Increase Decrease In Settlement Assets
IncreaseDecreaseInSettlementAssets
-5100000
ibio Increase Decrease In Settlement Assets
IncreaseDecreaseInSettlementAssets
-5100000
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
1015000
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
3257000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-627000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
494000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-74000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
975000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-21000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-5000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-481000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1649000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-18000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
618000
ibio Increase Decrease In Accrued Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesNoncurrent
791000
ibio Increase Decrease In Accrued Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesNoncurrent
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-100000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-86000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25466000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25977000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
5355000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4100000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
9711000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
6739000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
1760000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4300000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5232000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3900000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2100000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
692000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7015000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5604000
ibio Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
7851000
ibio Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
0
ibio Payments For Fractional Shares After Reverse Stock Split
PaymentsForFractionalSharesAfterReverseStockSplit
39000
ibio Payments For Fractional Shares After Reverse Stock Split
PaymentsForFractionalSharesAfterReverseStockSplit
0
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
50000
ibio Proceeds From Equipment Financing Loan
ProceedsFromEquipmentFinancingLoan
500000
ibio Proceeds From Equipment Financing Loan
ProceedsFromEquipmentFinancingLoan
0
ibio Payment Of Equipment Financing Loan
PaymentOfEquipmentFinancingLoan
62000
ibio Payment Of Equipment Financing Loan
PaymentOfEquipmentFinancingLoan
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
8523000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
77000
ibio Payments To Attain Term Note
PaymentsToAttainTermNote
22000
ibio Payments To Attain Term Note
PaymentsToAttainTermNote
322000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
144000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5820000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-439000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6115000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18857000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37696000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28672000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77404000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9815000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39708000
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
1769000
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
791000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
814000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
5489000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
158000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
249000
CY2023Q1 ibio Discontinued Operations Miscellaneous Expenses Income
DiscontinuedOperationsMiscellaneousExpensesIncome
3000
CY2022Q1 ibio Discontinued Operations Miscellaneous Expenses Income
DiscontinuedOperationsMiscellaneousExpensesIncome
1000
ibio Increase Decrease In Finance Lease Obligations For New Leases
IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
814000
ibio Increase Decrease In Finance Lease Obligations For New Leases
IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
0
ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
650000
ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
0
ibio Cost To Raise Capital Paid Directly From Gross Proceeds
CostToRaiseCapitalPaidDirectlyFromGrossProceeds
636000
ibio Cost To Raise Capital Paid Directly From Gross Proceeds
CostToRaiseCapitalPaidDirectlyFromGrossProceeds
0
ibio Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant
TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant
0
ibio Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant
TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant
25386000
us-gaap Notes Issued1
NotesIssued1
0
us-gaap Notes Issued1
NotesIssued1
22375000
ibio Non Cash Transaction Increase In Right Of Use Assets And Liabilities
NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
0
ibio Non Cash Transaction Increase In Right Of Use Assets And Liabilities
NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
5570000
ibio Non Cash Settlement Of Revenue Contract
NonCashSettlementOfRevenueContract
0
ibio Non Cash Settlement Of Revenue Contract
NonCashSettlementOfRevenueContract
580000
ibio Warrants Issued For Finance Lease Payment
WarrantsIssuedForFinanceLeasePayment
0
ibio Warrants Issued For Finance Lease Payment
WarrantsIssuedForFinanceLeasePayment
217000
ibio Lease Incentive For Construction In Progress
LeaseIncentiveForConstructionInProgress
0
ibio Lease Incentive For Construction In Progress
LeaseIncentiveForConstructionInProgress
82000
ibio Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed
NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed
0
ibio Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed
NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed
18000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
159000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
131000
us-gaap Interest Paid Net
InterestPaidNet
523000
us-gaap Interest Paid Net
InterestPaidNet
860000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.   Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (“we”, “us”, “our”, “iBio”, “iBio, Inc” or the “Company”) is an Artificial Intelligence (“AI”)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where it may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20230331x10q001.jpg" style="display:inline-block;height:269.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:531.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (“Tregs”) via antibody-dependent cellular cytotoxicity (“ADCC”), without disrupting activation of effector T-cells (“Teffs”) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (“IND”) enabling stage. We have contracted with a contract research organization (“CRO”) to assist with the development of the manufacturing process, which includes but is not limited to process and cell line development for the production of the drug substance and drug product. IBIO-101 is strategically positioned as a fast follower to Hoffman-La Roche’s RG6292 molecule that recently released Phase 1 clinical data. While RG6292 showed signs of efficacy, especially in combination with PD-L1 monoclonal antibody, and was well tolerated, we anticipate additional clinical research will be needed to determine whether different cancer types are more efficacious than others. As a result, we have decided to pause the IND enabling studies until additional data is released on RG6292. This approach will allow us to gather more information, thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly “switched on” which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CD3 antibody panel:</b> provides a range of CD3 affinities with cross-reactivity to non-human primates and increased the humanness of the antibody sequences. The antibody panel is intended to serve as one arm of T-cell-redirecting bispecific antibodies, a new class of therapeutic antibodies designed to simultaneously bind to T-cells via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MUC16:</b> a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has three additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university.  After careful consideration, in February 2023, the Company terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to the license agreement with the University of Pittsburgh, the Company’s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 – Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon three key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A patented machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than ”trial and error” antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (“PoC’) by up to four months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method for Protein Modelling to Design Engineered Peptides,” which, among other claims, covers a machine learning model for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">engineering peptides, including antibody epitope therapeutics.  Subject to any potential patent term extensions, the patent will expire on May 13, 2040.</p>
CY2023Q1 ibio Cash And Cash Equivalents Plus Debt Securities
CashAndCashEquivalentsPlusDebtSecurities
9800000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2022Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
69
CY2022Q4 ibio Employee Reduction Expenses
EmployeeReductionExpenses
1900000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities Current
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
100000
ibio Employee Reduction Expenses
EmployeeReductionExpenses
34600000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
17600000
ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
4900000
CY2023Q1 ibio Disposal Group Including Discontinued Operation Personnel Costs Including Severance
DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance
7500000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
205000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
143000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
25000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
48000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
180000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
95000
CY2023Q1 ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
837000
CY2022Q1 ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
2278000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
929000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
3211000
CY2023Q1 ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
-732000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1034000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
161000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
250000
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1015000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5644000
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
391000
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
438000
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
52000
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
201000
us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
339000
us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
237000
ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
6361000
ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
5128000
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
6165000
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
8659000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
17600000
ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
4933000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
34327000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
13787000
us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
606000
us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
372000
ibio Disposal Group Interest Expense Related Party
DisposalGroupInterestExpenseRelatedParty
810000
ibio Disposal Group Gain On Debt Forgiveness
DisposalGroupGainOnDebtForgiveness
607000
ibio Discontinued Operations Miscellaneous Expenses Income
DiscontinuedOperationsMiscellaneousExpensesIncome
4000
ibio Discontinued Operations Miscellaneous Expenses Income
DiscontinuedOperationsMiscellaneousExpensesIncome
-1000
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
610000
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
574000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-34598000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-14124000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
3900000
CY2023Q1 ibio Disposal Group Operating Lease Right Of Use Assets
DisposalGroupOperatingLeaseRightOfUseAssets
1944000
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
16424000
CY2023Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
18368000
CY2022Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
3900000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
35289000
CY2022Q2 ibio Disposal Group Non Current Assets Finance Lease Right Of Use Assets
DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets
74000
CY2022Q2 ibio Disposal Group Operating Lease Right Of Use Assets Noncurrent
DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent
1951000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
37314000
CY2022Q2 ibio Disposal Group Current Liabilities Finance Lease Obligations
DisposalGroupCurrentLiabilitiesFinanceLeaseObligations
46000
CY2023Q1 ibio Disposal Group Current Liabilities Operating Lease Obligations
DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
1944000
CY2022Q2 ibio Disposal Group Current Liabilities Operating Lease Obligations
DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
10000
CY2023Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1944000
CY2022Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
56000
CY2022Q2 ibio Disposal Group Noncurrent Liabilities Finance Lease Obligations
DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations
30000
CY2022Q2 ibio Disposal Group Noncurrent Operating Lease Obligations
DisposalGroupNoncurrentOperatingLeaseObligations
1941000
CY2022Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
1971000
us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
273000
us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
1532000
ibio Disposal Group Amortization Of Finance Lease Right Of Use Assets
DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
20000
ibio Disposal Group Amortization Of Finance Lease Right Of Use Assets
DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
587000
us-gaap Capital Expenditure Discontinued Operations
CapitalExpenditureDiscontinuedOperations
1041000
us-gaap Capital Expenditure Discontinued Operations
CapitalExpenditureDiscontinuedOperations
28384000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
17600000
ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
4933000
ibio Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period
DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
1542000
ibio Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period
DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
791000
ibio Unpaid Fixed Assets Attributable To Discontinued Operations
UnpaidFixedAssetsAttributableToDiscontinuedOperations
460000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3300000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
426000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
423000
CY2023Q1 ibio Percentage Of Collateral Required
PercentageOfCollateralRequired
0.05
CY2021Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
7500000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6562000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22676000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
9815000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
28672000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March 31, 2023 and June 30, 2022, amounts in excess of insured limits were approximately $6,300,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended March 31, 2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended March 31, 2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from two customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the nine months ended March 31, 2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the nine months ended March 31, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract.  The Company also generated $438,000 of revenue reported in discontinued operations from six customers.</p>
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6300000
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18200000
CY2021Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
7500000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11029000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
184000
CY2022Q2 us-gaap Debt Securities Current
DebtSecuritiesCurrent
10845000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
8054000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
2791000
CY2022Q2 us-gaap Debt Securities Current
DebtSecuritiesCurrent
10845000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
74000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
67000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
269000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19213000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
136000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
678000
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11383
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3603000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3068000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1967000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4593000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1373000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
235000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4358000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1373000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2023Q1 ibio Fixed Assets Held For Sale
FixedAssetsHeldForSale
16424000
CY2022Q2 ibio Fixed Assets Held For Sale
FixedAssetsHeldForSale
35289000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
17600000
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
25000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5946000
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
400000
ibio Impairment Of Intangible Assets Gross Of Reversals
ImpairmentOfIntangibleAssetsGrossOfReversals
5946000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
400000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5270000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000
ibio Reversal Of Intangible Asset Impairment
ReversalOfIntangibleAssetImpairment
5381000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
676000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
400000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
565000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
390000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4175000
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
828000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5003000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
122000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
121000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
565000
CY2022Q4 ibio Equipment Financing Amount Borrowed
EquipmentFinancingAmountBorrowed
500000
CY2022Q4 ibio Lessee Equipment Lease Term Of Contract
LesseeEquipmentLeaseTermOfContract
P36M
CY2022Q4 ibio Equipment Financing Lease Imputed Interest Rate
EquipmentFinancingLeaseImputedInterestRate
0.1062
CY2022Q4 ibio Equipment Leasing Monthly Installment Payable
EquipmentLeasingMonthlyInstallmentPayable
16230
CY2023Q1 ibio Equipment Financing Balance
EquipmentFinancingBalance
438000
CY2023Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
195
CY2023Q1 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
195
CY2023Q1 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
114
CY2023Q1 us-gaap Contractual Obligation
ContractualObligation
504
CY2021Q2 ibio Lessor Finance Lease Monthly Rent
LessorFinanceLeaseMonthlyRent
3819
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
68000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
16000
CY2023Q1 us-gaap Lease Cost
LeaseCost
84000
CY2023Q1 ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
62000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
156000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
33000
us-gaap Lease Cost
LeaseCost
189000
ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
144000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
678000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
265000
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M2D
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0950
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
319000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
320000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
133000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
772000
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11383
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P88M
CY2021Q3 ibio Lessee Operating Lease Monthly Rent
LesseeOperatingLeaseMonthlyRent
51223
CY2021Q3 ibio Lessee Operating Lease Annual Percentage Increase In Base Rent
LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
0.03
CY2021Q3 us-gaap Tenant Improvements
TenantImprovements
81860
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2023Q1 ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
141000
CY2022Q1 ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
141000
CY2023Q1 ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
103000
us-gaap Operating Lease Cost
OperatingLeaseCost
422000
us-gaap Operating Lease Cost
OperatingLeaseCost
313000
ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
422000
ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
313000
ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
154000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6279000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6746000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24379000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
377000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Year One
LesseeOperatingLeaseImputedInterestToBePaidYearOne
249000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year One
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
626000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
424000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Two
LesseeOperatingLeaseImputedInterestToBePaidYearTwo
220000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Two
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
644000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
476000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Three
LesseeOperatingLeaseImputedInterestToBePaidYearThree
188000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Three
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
664000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
532000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Four
LesseeOperatingLeaseImputedInterestToBePaidYearFour
151000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Four
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
683000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
593000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Five
LesseeOperatingLeaseImputedInterestToBePaidYearFive
111000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Five
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
704000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1200000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid After Year Five
LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
82000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid After Year Five
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
1282000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3602000
CY2023Q1 ibio Lessee Operating Lease Imputed Interest To Be Paid Total
LesseeOperatingLeaseImputedInterestToBePaidTotal
1001000
CY2023Q1 ibio Lessee Operating Lease Liability Principal And Imputed Interest
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
4603000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
377000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3225000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6279000
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6746000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-24379000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-19125000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
88000
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1015000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5644000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-34598000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-14124000
CY2023Q1 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-7294000
CY2022Q1 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-12390000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-58977000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-33337000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13184000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8719000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10592000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8719000
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.47
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.77
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.30
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.20
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.08
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.65
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-3.27
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.82
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6848000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
699000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
385000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1213000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2426000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2893000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0321
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0361
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1552
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1693
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2023Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
56000
CY2022Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
54000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
116000

Files In Submission

Name View Source Status
ibio-20230331_cal.xml Edgar Link unprocessable
ibio-20230331_def.xml Edgar Link unprocessable
0001558370-23-009707-index-headers.html Edgar Link pending
0001558370-23-009707-index.html Edgar Link pending
0001558370-23-009707.txt Edgar Link pending
0001558370-23-009707-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ibio-20230331.xsd Edgar Link pending
ibio-20230331x10q.htm Edgar Link pending
ibio-20230331x10q001.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ibio-20230331x10q002.jpg Edgar Link pending
ibio-20230331xex10d7.htm Edgar Link pending
ibio-20230331xex10d7001.jpg Edgar Link pending
ibio-20230331xex10d8.htm Edgar Link pending
ibio-20230331xex31d1.htm Edgar Link pending
ibio-20230331xex31d2.htm Edgar Link pending
ibio-20230331xex32d1.htm Edgar Link pending
ibio-20230331xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
ibio-20230331_lab.xml Edgar Link unprocessable
ibio-20230331_pre.xml Edgar Link unprocessable
ibio-20230331x10q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending